Adam has worked for Pfizer for 12 years. His current role is Senior Director in Pfizer’s Global Health and Value Innovation Center, working on new approaches to market access. Previously, Adam has worked in Pfizer’s international policy division and led Pfizer’s work on science policy in Europe for several years. Adam initially joined Pfizer as part of the government affairs team in the UK, working on healthcare reform and health economics.
Rare diseases have been a theme of Adam’s work at Pfizer and until 2017 he co-chaired the EFPIA/EuropaBio joint task force on rare diseases and orphan medicinal products, and sat on the EU Expert Group on Rare Diseases and the therapies committee of the International Rare Diseases Research Consortium (IRDiRC).
Before joining Pfizer, Adam worked for a variety of government and public sector organisations, including the Prime Minister’s Strategy Unit, the House of Lords Science and Technology Committee, and the Commission for Patient and Public Involvement in Health.
Adam also spent three years as a post-doctoral researcher at the Space Science Department of the Rutherford Appleton Laboratory, Oxfordshire